AstraZeneca (AZ) announced 2025 first-half revenue of USD 28 billion, an 11% year-on-year increase, driven by strong oncology performance. The star performer was ADC Enhertu (trastuzumab deruxtecan), which generated USD 1.3 billion for AZ and USD 2.3 billion globally (including Daiichi Sankyo's share), up 29% from 2024.

Tagrisso (osimertinib) maintained steady growth with USD 3.5 billion in sales (+10%), while respiratory drug Tezspire (tezepelumab) grew 73% to USD 1.2 billion. Rare disease drug Ultomiris (ravulizumab) also delivered robust growth, with sales reaching USD 2.2 billion (+24%). China contributed USD 3.5 billion (+5%), representing 13% of global revenue.

The company highlighted progress in its pipeline, including the recent US approval of ADC Datroway (datopotamab deruxtecan) for breast and lung cancers. AZ expects full-year revenue growth in the high single-digits, supported by upcoming Phase III readouts in oncology and cardiovascular-metabolic diseases.

According to PharmCube's NextBiopharm® database, AZ has its main focus on oncology and rare diseases. Click here to request a free trial for NextBiopharm®.